# BPC-157: research overview — Peptide Download > BPC-157 is a synthetic 15-amino-acid peptide studied in animal models of tissue repair. A plain-English summary of the research evidence, how it works, and the important caveats — including thin human data and regulatory controversy. Body Protection Compound 157 — a gastric peptide with a large animal-model literature and an extremely thin human dataset. Here is what the science actually shows, and where it stops. ## The short version BPC-157 is a synthetic peptide fifteen amino acids long, derived from a partial sequence of a protein found in human gastric juice. It has been studied for roughly three decades — mostly in rat and mouse models — across a wide range of injury types: tendons, ligaments, muscle, gut lining, nerve, and bone. Its repair effects in animal models are most consistently linked to *angiogenesis*: the growth of new blood vessels into damaged tissue. The best-characterized molecular pathway involves up-regulating and activating the VEGFR2 receptor with downstream nitric-oxide signaling [4]. The honest caveat, acknowledged in 2025 reviews, is that human evidence is extremely limited. A first-in-human safety pilot involved just two adults [1]. A 2025 narrative review counted only three small human pilot studies total and described rigorous large-scale trials as lacking [2]. BPC-157 is not approved as a medicine anywhere, and the FDA in 2023 placed it in a category of substances not currently eligible for pharmacy compounding pending further evaluation. **No human dose is recommended or implied on this page.** ## What it is BPC-157 stands for Body Protection Compound 157. Its amino-acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val — fifteen residues. It is a stable, synthetic peptide: that 'stable' descriptor matters because it means the compound resists enzymatic breakdown in the stomach and bloodstream more readily than most short peptides, which is part of why it can be studied in multiple routes of administration in animal models. Other designators in the scientific literature include PL 14736, PLD-116, PL-10, and the research designation Bepecin. Its molecular formula is C62H98N16O22. BPC-157 is classified by researchers as a cytoprotective and regenerative research peptide, meaning it is studied for its potential to protect tissue from damage and to support repair processes — not to treat any specific diagnosed disease in humans. It is sold for laboratory research use only and has no established human therapeutic indication. ## How it works The most consistently reported mechanism in the published literature is pro-angiogenic signaling through the VEGFR2 (also called KDR) receptor. Hsieh et al. [4] demonstrated in vascular endothelial cells and in a rat hindlimb ischemia model that BPC-157 up-regulates VEGFR2 expression and promotes its internalization, with downstream activation of the VEGFR2-Akt-eNOS (nitric-oxide synthase) pathway. This results in increased vessel density and accelerated blood-flow recovery in ischemic tissue. Effects were blocked by inhibiting endocytosis, confirming that receptor internalization is part of the mechanism. Additional reported pathways include: - **FAK-paxillin signaling** — involved in cell migration toward wounds, a component of tissue repair across injury types. - **Growth hormone receptor sensitization in tendon fibroblasts** — BPC-157 has been shown to increase GH-receptor signaling in cultured tendon cells, a potential mechanism for the tendon-repair effects observed in animal work [2]. - **Modulation of serotonin systems** — in rodent studies BPC-157 has been shown to alter brain serotonin activity. This is the basis for a mechanism-level concern about combining it with serotonin-affecting medicines, though no human interaction study has been conducted. The first formal pharmacokinetic characterization of BPC-157 [3] found linear kinetics in rats and beagle dogs: a short elimination half-life (under 30 minutes), modest intramuscular bioavailability (~14–19% in rats, ~45–51% in dogs), and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism. ## What the research shows **Gastric cytoprotection (2004).** Xue et al. [5] — the foundational study type for BPC-157 — showed it reduced gastric ulcer area and accelerated ulcer healing in Wistar rats, with intramuscular delivery outperforming intragastric. Ulcer inhibition ratios of 45.7–65.6% were observed at higher doses. **VEGFR2 and angiogenesis (2017).** Hsieh et al. [4] demonstrated the VEGFR2 mechanism across three experimental systems: chick chorioallantoic membrane, rat hindlimb ischemia, and human vascular endothelial cells. Vessel density increased in all three; blood-flow recovery in ischemic muscle was accelerated. **Pharmacokinetics (2022).** He et al. [3] characterized BPC-157's absorption, distribution, metabolism, and excretion in rats and dogs. The half-life is short, IM bioavailability is modest, and the compound breaks down into normal amino-acid fragments — there is no unusual accumulation or unusual metabolite. **First human safety pilot (2025).** Lee and Burgess [1] gave intravenous BPC-157 at up to 20 mg to two healthy adults (a 58-year-old male and a 68-year-old female). No adverse events were observed, and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers were detected. The study's limitation — two participants — makes it an early safety signal rather than evidence of safety in a population. **2025 narrative review.** McGuire et al. [2] reviewed the full BPC-157 literature from a musculoskeletal perspective. Their key conclusions: only three small human pilot studies exist, rigorous large-scale controlled trials are lacking, a large proportion of foundational research comes from a single research group (a replication concern they name explicitly), and BPC-157 should be treated as investigational and used with caution given regulatory controversy and non-regulated availability. **The evidence ceiling.** Almost every positive BPC-157 finding in the literature is in rodents. The human dataset is genuinely thin, and the 2025 review notes it plainly. Animal findings do not automatically translate to humans — that is a principle of drug development, not a dismissal of the preclinical work. ## Reported effects, cautions and safety **Reported effects from research-use communities (anecdotal, not clinical evidence)** The following patterns come from peptide user forums, wellness-clinic blogs, and published qualitative discussions of online reports. They are personal accounts, not controlled observations. - *Faster recovery from tendon, ligament, and joint injuries* — very commonly reported. People describe stubborn tendon and joint problems easing, sometimes within one to three weeks. The most cited reason people try BPC-157. Anecdotal. - *Less joint stiffness and pain* — frequently reported. Many users describe day-to-day stiffness easing and painful movements becoming easier, sometimes within one to two weeks. Anecdotal. - *Improved digestive or gut symptoms* — frequently reported. Users describe less bloating, cramping, and urgency, and better tolerance of foods that previously caused problems. Anecdotal. - *Faster skin and wound healing* — occasionally reported. Some users describe cuts or minor skin wounds seeming to close faster, linked by them to the peptide's reported pro-angiogenic effect. Anecdotal. - *Better sleep, mood, or stress tolerance* — occasionally reported. Commentators note this could easily reflect better sleep from reduced pain rather than a direct brain effect. Anecdotal. - *Injection-site redness, stinging, or a small bump* — very commonly reported adverse effect. Generally described as minor and brief. Anecdotal. - *Nausea or mild stomach upset* — frequently reported, especially in the first days. Usually described as passing on its own. Anecdotal. - *Fatigue in the first week* — occasionally reported. Described as settling with continued use. Anecdotal. - *Dizziness or lightheadedness after injecting* — occasionally reported, possibly related to the peptide's effects on the nitric-oxide system. Anecdotal. **Cautions grounded in the published literature** - **Extremely thin human evidence.** Almost everything known about BPC-157 comes from rodent studies. Large, rigorous controlled trials in humans are absent [1, 2]. - **Single-group replication concern.** A large share of the foundational literature comes from one research group and collaborators; independent replication is limited [2]. - **Not an approved drug; unregulated products vary.** BPC-157 is not approved anywhere. Products move through non-regulated channels, so identity, purity, and actual content are unverified outside formal studies [2]. - **Strong pro-angiogenic activity — theoretical cancer concern.** BPC-157's repair effects are tied to new blood-vessel formation through VEGFR2 [4]. Because tumors also depend on angiogenesis, there is a mechanism-based theoretical concern in people with active or suspected cancer. - **Possible interaction with serotonin-affecting medicines.** Rodent work shows BPC-157 alters brain serotonin activity and has modified the course of drug-induced serotonin syndrome. A mechanism-based concern for people taking serotonin-raising medicines; no human interaction study exists. - **Banned in competitive sport.** BPC-157 is prohibited at all times by WADA under the S0 non-approved-substances category. - **Unstudied in pregnancy, breastfeeding, and children.** No safety data exist for these populations. ## Where it fits in the research-fundamentals map BPC-157 represents this desk's tissue-repair and angiogenesis territory — the most extensively studied research peptide in animal models of healing, with one of the thinnest human evidence bases. It is worth understanding in comparison with [Ipamorelin](/ipamorelin) (whose GH-axis effects also touch tissue repair), [GHK-Cu](/ghk-cu) (which works through collagen and matrix synthesis rather than blood-vessel growth), and [Semaglutide](/semaglutide) (which sits at the opposite end of the evidence spectrum, with large replicated human trials). [Compare all four](/compare). --- A calibrated literature digest — curious about the evidence, disciplined about what the evidence actually says.